The progression of Parkinson disease: A hypothesis

Neurology

Volumn 68, Issue 12, 2007, Pages 948-952

  Lang, Anthony E ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DOPAMINE; GLUTATHIONE; IRON; NEUROMELANIN;

ARTICLE; BRAIN REGION; CALCIUM HOMEOSTASIS; CELL LOSS; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; EXCITOTOXICITY; HUMAN; HYPOTHESIS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METABOLISM; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

ANIMALS; AUTONOMIC PATHWAYS; DISEASE PROGRESSION; DOPAMINE; HUMANS; NERVE DEGENERATION; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; RHOMBENCEPHALON; SUBSTANTIA NIGRA;

EID: 34147181610     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000257110.91041.5d     Document Type: Article

References (28)

1. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449-458.
2. Lang AE, Obeso JA. Current challenges in Parkinson's disease: restoring the nigrostriatal dopamine system will not suffice. Lancet Neurol 2004;3:309-316.
3. Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
4. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004;55:761-765.
5. Braak H, Del Tredici K, Rüb U, De Vos RAI, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
6. Del Tredici K, Rüb U, De Vos RAI, Bohl JRE, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-426.
7. 11C-WAY 100635 PET study. Neurology 2003;60:601-605.
8. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001;16:41-46.
9. Ponsen MM, Stoffers D, Booij J, Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-181.
10. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462.
11. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-339.
12. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005;65:1442-1446.
13. Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000;41:71-77.
14. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 2003;62:363-367.
15. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998;51:2-9.
16. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
17. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57-87.
18. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann NY Acad Sci 2000;899:112-120.
19. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53:S26-S36.
20. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003;179:38-46.
21. Hirsch EC, Mouatt A, Thomasset M, Javoy-Agid F, Agid YA, Graybiel AM. Expression of calbindin D28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution in Parkinson's disease. Neurodegeneration 1992;1:83-93.
22. Van den MP, Luk KC, Ste-Marie L, et al. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 2003;130:2535-2542.
23. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998;44:S115-120.
24. Teismann P, Tieu K, Cohen O, et al. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003;18:121-129.
25. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
26. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003;184:S68-S79.
27. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006;66:845-851.
28. Paisan-Ruiz C, Lang AE, Kawarai T, et al. LRRK2 gene in Parkinson disease - mutation analysis and case control association study. Neurology 2005;65:696-700.